|
Neuroblastoma
|
0.040 |
AlteredExpression
|
disease |
LHGDN |
Remarkably, mAb-mediated masking of the 4Ig-B7-H3 molecule on cell transfectants or on freshly isolated neuroblastoma cells resulted in enhancement of natural killer-mediated lysis of these target cells.
|
15314238 |
2004 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Large subcutaneous H22 HCCs (0.7-0.8 cm in diameter) established in BALB/c mice were rapidly and completely eradicated when intratumoral administration of As(2)O(3) was preceded by in situ gene transfer of B7H3.
|
16217749 |
2006 |
|
Liver carcinoma
|
0.350 |
Therapeutic
|
disease |
CTD_human |
Large subcutaneous H22 HCCs (0.7-0.8 cm in diameter) established in BALB/c mice were rapidly and completely eradicated when intratumoral administration of As(2)O(3) was preceded by in situ gene transfer of B7H3.
|
16217749 |
2006 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, combining B7H3-mediated immunotherapy with As(2)O(3) warrants investigation as a therapeutic strategy to combat HCC, and other malignancies.
|
16217749 |
2006 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, our data present 4Ig-hB7H3 as a tumor-associated antigen and suggests a novel biological role of 4Ig-hB7H3 in tumor progression and metastasis.
|
18690846 |
2008 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The number of infiltrating lymphoid cells in the tumor tissues that express B7-H3 was much lower than those that did not, but there is no significant correlation between ILT-4 expression and disease progression including nodal metastasis.
|
18625675 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, our data present 4Ig-hB7H3 as a tumor-associated antigen and suggests a novel biological role of 4Ig-hB7H3 in tumor progression and metastasis.
|
18690846 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The number of infiltrating lymphoid cells in the tumor tissues that express B7-H3 was much lower than those that did not, but there is no significant correlation between ILT-4 expression and disease progression including nodal metastasis.
|
18625675 |
2008 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, our data present 4Ig-hB7H3 as a tumor-associated antigen and suggests a novel biological role of 4Ig-hB7H3 in tumor progression and metastasis.
|
18690846 |
2008 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion.
|
18690846 |
2008 |
|
Carcinogenesis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Osteosarcoma of bone
|
0.050 |
Biomarker
|
disease |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Childhood Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Rheumatoid Arthritis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Immunohistological sections of RA synovial tissue showed strong staining for B7-H3 on FLS.
|
18292521 |
2008 |
|
Rheumatoid Arthritis
|
0.040 |
Biomarker
|
disease |
LHGDN |
Interactions of T cells with fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3.
|
18292521 |
2008 |
|
melanoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.
|
18694993 |
2008 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data show for the first time that B7-H3 may have a critical role in pancreatic cancer and provide the rationale for developing a novel cancer immunotherapy against this fatal disease.
|
19844235 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B7-H3 blockade promoted CD8(+) T-cell infiltration into the tumour and induced a substantial anti-tumour effect on murine pancreatic cancer.
|
19844235 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Differential modulation of this key immunoinhibitory molecule in tumor versus normal tissues may advance both cell-mediated immunotherapy and antibody-based targeted strategies using the B7-H3-specific mAb 8H9.
|
19584290 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients with high tumor B7-H3 levels had a significantly better postoperative prognosis than patients with low tumor B7-H3 levels (p = 0.0067).
|
20035626 |
2009 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data show for the first time that B7-H3 may have a critical role in pancreatic cancer and provide the rationale for developing a novel cancer immunotherapy against this fatal disease.
|
19844235 |
2009 |